retatrutide type 2 diabetes phase 2 trial hba1c Delivers Significant Hemoglobin A1C Reduction, Weight Loss in 3 Retatrutide—A Game Changer in Obesity

10.1186/s12906-018-2180-2 143 WatanabeS.OkoshiH.YamabeS.ShimadaM

[PMC free article: PMC8576431] [PubMed: 34088712] 195

"These findings have immediate and potentially transformative implications for how these blockbuster drugs are prescribed and for the development of new, more effective treatments with better tolerability," noted Mayo Clinic researchers in the paper titled "A GENETIC RISK SCORE ASSOCIATED WITH NAUSEA RESULTING FROM GLP-1 AGONIST TREATMENT." Additional findings from the study revealed: High-CTSGRS patients were also significantly more likely to report headaches (odds ratio of 5.4) A trend indicating individuals with high-CTSGRS were more prone to experiencing GI-related side effects in general (73% vs

No aggravating factors were identified, including pregnancy

Female biology is more susceptible to telogen effluvium for several reasons